PON1 and rheumatoid arthritis: Our previous work has linked suppressed PON1 activity to both subclinical atherosclerosis measured by carotid plaque [7], as well as risk of cardiovascular events in a large, ~ 2000 patient developmental program of the RA therapeutic, tofacitinib [24].